pyrroles has been researched along with Essential Hypertension in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ichikawa, S; Sugimoto, K; Tsutsumi, J; Yamakawa, S | 1 |
| Ito, S; Itoh, H; Okuda, Y; Rakugi, H; Yamakawa, S | 1 |
| Ito, S; Itoh, H; Okuda, Y; Rakugi, H; Yamakawa, S; Yoshimura, M | 1 |
| Bespalova, ID; Kaliuzhin, VV; Mediantsev, IuA; Murashev, BIu; Osikhov, IA; Riazantseva, NV | 1 |
2 trial(s) available for pyrroles and Essential Hypertension
| Article | Year |
|---|---|
Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Drug Therapy, Combination; Essential Hypertension; Female; Humans; Hyperkalemia; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Pyrroles; Sulfones; Treatment Outcome | 2019 |
Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study).
Topics: Aged; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Eplerenone; Essential Hypertension; Female; Humans; Male; Middle Aged; Pyrroles; Sulfones; Treatment Outcome | 2020 |
2 other study(ies) available for pyrroles and Essential Hypertension
| Article | Year |
|---|---|
Antihypertensive Effect of Long-Term Monotherapy with Esaxerenone in Patients with Essential Hypertension: Relationship Between Baseline Urinary Sodium Excretion and Its Antihypertensive Effect.
Topics: Antihypertensive Agents; Biomarkers; Blood Pressure; Essential Hypertension; Humans; Hypertension; Pyrroles; Sodium; Sulfones | 2022 |
[Effect of atorvastatin on pro-inflammatory status (in vivo and in vitro) in patients with essential hypertension and metabolic syndrome].
Topics: Anticholesteremic Agents; Atorvastatin; Cytokines; Dose-Response Relationship, Drug; Drug Monitoring; Essential Hypertension; Female; Heptanoic Acids; Humans; Hypertension; Inflammation; Leukocytes, Mononuclear; Male; Metabolic Syndrome; Middle Aged; Patient Acuity; Prospective Studies; Pyrroles; Reactive Oxygen Species; Severity of Illness Index; Treatment Outcome | 2014 |